Revenue from collaboration agreements (Tables)

6 Months Ended

Jun. 30, 2022

Summary of revenue from collaboration agreements explanatory

The

Group earned revenue from collaboration agreements from the following collaborators during the three and six months ended June 30, 2022 and 2021:


	Three months ended June 30,				Six months ended June 30,
	2022		2021		2022		2021
	(Euros in thousands)				(Euros in thousands)

Amgen		—		260		—		517
Genmab		4,125		2,105		7,044		4,341
BMS		12,107		1,297		110,532		4,590
GSK		983		1,527		2,547		3,144

Total		17,215		5,189		120,123		12,592

Summary of Deferred revenue related to the collaboration agreements

The Group expects to recognize the remaining deferred revenue balance into revenue as it performs the related performance obligations under each contract. Deferred revenue related to the collaboration agreements consists of the following as of June 30, 2022 and December 31, 2021:


	As of
	June 30, 2022		December 31, 2021
	(Euros in thousands)

Current		78,394		50,402
Non-current		115,321		48,225

Total		193,715		98,627